Alcon's Eye Allergy Drug, PATANOL(R) Ophthalmic Solution, Approved in Japan

PATANOL(R) solution provides both mast cell stabilizing andanti-histamine properties in a single molecule, providing patientswith rapid, effective and lasting relief from the signs and symptomsof allergic conjunctivitis, an allergen-induced inflammatory responsecharacterized by ocular itching, redness and tearing.

Japan is the world's second largest ocular allergy market andtherefore represents a significant business opportunity for thecompany to expand sales of PATANOL(R) solution, according to AlconJapan President Scott Manning.

"The approval of PATANOL(R) solution is an important developmentfor Alcon," said Manning. "We anticipate launching this product inJapan this year and will be expanding our sales force to maximize thisopportunity. We expect PATANOL(R) solution to be a contributor to ourfuture growth and also anticipate that this product will be adopted bythe medical community and will provide optimal ocular relief andcomfort to patients who suffer from eye allergies."

PATANOL(R) solution is approved in 83 countries including theUnited States where it has become the leading product for thetreatment for ocular allergy.

About Alcon

Alcon, Inc. (NYSE:ACL) is the world's leading eye care companywith sales of $4.4 billion in 2005. Alcon, which has been dedicated tothe ophthalmic industry for more than 50 years, develops, manufacturesand markets pharmaceuticals, surgical equipment and devices, contactslens care solutions and other vision care products that treatdiseases, disorders and other conditions of the eye. For moreinformation on Alcon, Inc., visit the Company's web site atwww.alconinc.com.

Caution Concerning Forward-Looking Statements. This press releasecontains forward-looking statements within the meaning of the PrivateSecurities Litigation Reform Act of 1995. These statements involveknown and unknown risks, uncertainties and other factors which maycause our actual results, performance or achievements to be materiallydifferent from any future results, performances or achievementsexpressed or implied by our forward-looking statements. Thesestatements reflect the views of our management as of the date of thispress release with respect to future events and are based onassumptions and subject to risks and uncertainties. Given theseuncertainties, you should not place undue reliance on theseforward-looking statements.